S R-B1 (scavenger receptor class B type 1), encoded by the gene SCARB1, is a multiligand membrane receptor, 1-5 which binds high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very low-density lipoprotein. 1-4 SR-B1 binding to lipoproteins results in selective uptake of cholesteryl esters. [2] [3] [4] Mice overexpressing Scarb1 are protected against atherosclerosis, 6,7 while Scarb1-deficient mice have increased atherosclerosis, 8,9 despite also having increased HDL, 8,9 likely because of decreased hepatic delivery and clearance of cholesterol. 8 Although SR-B1 has been studied in animal models, its role in human lipoprotein metabolism is not clear. Studies of SCARB1 polymorphisms, 10-12 a report of a heterozygous SCARB1 mutation, 13 and a recent report of a rare homozygous mutation in a subject with high HDL 14 suggest a role in regulating HDL levels in both sexes and possibly LDL levels in women, 10,12 but no human SCARB1 mutations affecting lipoprotein (a) (Lp(a)) have been reported.
control. [15] [16] [17] [18] [19] Although structurally and compositionally similar to LDL, Lp(a) is a relatively poor ligand for the LDL receptor 20 and the lipoprotein receptor-related protein. 21 Lp(a) can bind to the very low-density lipoprotein receptor, but receptor-defective mice showed only a modest delay in catabolism of Lp(a), 22 suggesting other unidentified receptor(s).
We found that SR-B1 may be a receptor for Lp(a). 5 In vitro, SR-B1 can bind Lp(a) and mediate intracellular transport of Lp(a). Cells overexpressing SR-B1 exposed to dual labeled Lp(a) took up the lipid moiety of the Lp(a) particle much more than the protein, supporting selective lipid transport. 5 Transgenic mice overexpressing human SR-BI in liver had greater plasma clearance of [ 3 H] cholesteryl etherlabeled Lp(a), whereas Scarb1 knockout mice had less clearance. Because SR-B1 mediates lipid uptake from both HDL and Lp(a), we hypothesized that human SR-B1 deficiency may be characterized by a combined increase in plasma levels of HDL cholesterol (HDLC) and Lp(a). To test this, 2 cohorts were screened for combined elevations of HDL and Lp(a) to examine its association with genetic variants in the SCARB1 gene and with diminished function of the translated SR-B1 protein.
Materials and Methods

Study Populations
An index subject with high levels of HDLC and Lp(a) was identified in the National Institutes of Health (NIH) Lipid Clinic. SCARB1 was sequenced using methods described below. To further investigate the relationship between SCARB1 mutations and the high HDLC/high Lp(a) phenotype, 2 
cohorts (Johns Hopkins GeneSTAR [Genetic Study of Atherosclerosis Risk] and the CCHS [Copenhagen City
Heart Study]) were studied.
GeneSTAR is a prospective study of families identified from probands hospitalized with early-onset acute coronary syndromes <60 years of age. The cohort included 543 healthy non-coronary artery disease (CAD) siblings, aged 30 to 75 years. 23 The study was approved by the Johns Hopkins Medicine Institutional Review Board, and all participants gave written informed consent. Subjects underwent risk factor screening and measurement of plasma Lp(a) after a 12-hour overnight fast. Blood pressure and blood lipids (total cholesterol, HDLC, triglycerides, and LDL cholesterol [LDLC]) were assessed as previously described. 23 LDLC was estimated using the Friedewald formula. Lipoprotein subclass assays were performed by LipoScience Inc (Raleigh, NC) using nuclear magnetic resonance spectroscopy (see Methods in the Data Supplement). Type 2 diabetes mellitus was defined as a physician-diagnosed history, a measured fasting glucose level ≥6.99 mmol/L (126 mg/dL), and use of prescribed hypoglycemic medications. Hypertension was defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg and use of prescribed antihypertensive medications.
CCHS is a prospective study of CAD risk factors in the Copenhagen Central Person Register, with the subjects drawn randomly to represent the adult general population. 24 The cohort included 5835 non-CAD participants with measurements of fasting lipids and Lp(a). Total cholesterol, HDLC, and triglycerides were measured using colorimetric and turbidimetric assays. 25 LDLC was calculated using the Friedewald formula. Hypertension was defined as use of antihypertensive medication, a systolic blood pressure >140 mm Hg, or diastolic blood pressure >90 mm Hg. Diabetes mellitus was defined by self-report, use of hypoglycemic drugs, or a measured nonfasting plasma glucose >11 mmol/L. The study was approved by Herlev University Hospital and a Danish ethical committee, and all participants gave written informed consent.
Measurement of Lp(a)
In GeneSTAR, plasma Lp(a) concentration was measured in nmol/L in the Northwest Lipid Research Laboratory (Seattle, WA) by ELISA using an antibody against the apo(a) component of Lp(a). 26 In CCHS, Lp(a) concentration was measured by a turbidimetric assay (Technicon Axon autoanalyzer, Miles Inc, Tarrytown, NY) using an antibody against the apo(a) component. 24 For additional details, see Methods in the Data Supplement.
Sequencing of the SCARB1 Gene
Sequencing of the SCARB1 gene was performed in 18 subjects (1 from the NIH, 8 from GeneSTAR, and 9 from CCHS) with combined high levels of HDLC (>80 mg/dL) and Lp(a) (>100 nmol/L in GeneSTAR and >100 mg/dL in CCHS and the NIH patient). Genomic DNA was extracted from white blood cells (Qiagen kit, Valencia, CA) and amplified into 4 large fragments with SCARB1 primers ( Table I in the Data Supplement) by high fidelity polymerase chain reaction (PCR; Roche Applied Science, Indianapolis, IN). The PCR fragments were inserted into a Topo TA-Clone vector (Invitrogen, Carlsbad, CA) and sequenced (BigDye-terminator chemistry; Perkin-Elmer/Applied Biosystems, Foster City, CA) with vector and intronic primers ( Table II in the Data Supplement) . For the NIH patient and GeneSTAR subjects, sequencing included all 13 exons with 40 bp of each intron-exon junction in both SCARB1 splice variants 1(v1) and 2 (v2). Additionally, a direct PCR sequence method was used for sequencing of the proximal promoter (400 bp). For the CCHS cohort, the promoter and exon 1 were not sequenced. For DNA methylation sequencing, bisulfite was used to convert cytosine to uracil, while 5-methylcytosine remained nonreacted. Converted genomic DNA was amplified by PCR and sequenced (Methods in the Data Supplement). The predicted effect of genetic variants on SR-B1 function was calculated by profile extraction from sequence alignments using position-specific independent counts. 27 
In Vitro Mutagenesis and Cellular Experiments of Lipid Uptake
Wild-type human SCARB1 cDNA was generated as described. 5 Sitedirected mutagenesis by overlap PCR was used to produce all mutations in SCARB1 cDNA using mutagenesis primers (Tables II and III in the Data Supplement). All SCARB1 cDNA constructs were cloned into pcDNA3.1 (Invitrogen, Carlsbad, CA). For 2 intronic mutations (the intron 4 acceptor [ (-14] T/G and the compound mutation intron 4 -53 m C>T and intron 5 +54, 55 m CG>CA), minigene constructs consisting of the 4.4 kb fragment containing exons 4, 5, 6 and introns 4 and 5 were generated by PCR using the subject's own genomic DNA for the wild-type and each mutation. All SCARB1 gene constructs were confirmed by sequencing. SCARB1 constructs were transfected into 80% confluent HEK293 cells using Effectene transfection reagent (Qiagen, Valencia, CA). For stable transfection, cell clones were grown in DMEM growth medium containing 2 mg/mL G418 for 2 weeks and maintained thereafter with 0.25 mg/mL G418.
[ 3 H] cholesteryl ether-labeled HDL 3 and [ 3 H] cholesteryl etherlabeled Lp(a) were prepared as described. 5, 28 After cells grew to 95% confluence, 3H-labeled lipoproteins were added to the culture medium at different concentrations and time points. Cells were washed 4× with PBS and harvested with 0.01 N NaOH and 0.1% SDS solution. The cell lysates were used to measure cell-associated lipoproteins, expressed as nanogram-labeled lipoprotein per milligram cell protein.
Statistics
Quantitative functional assays were analyzed with t tests and represent at least 3 independent experiments. Regressions using the general estimating equation 29 to adjust for nonindependence of families were used for comparison of lipids in the siblings with or without SCARB1 variants.
Measurement of Apo(a) Isoforms, Northern and Western Analyses, DNA Methylation Assay, and Plasmid Construction
See Data Supplement.
Results
Prevalence of High HDLC/High Lp(a) Phenotype
The prevalence of the combined phenotype was determined in GeneSTAR (n=543) and CCHS (n=5835) and was defined as the co-occurrence of high plasma levels of HDLC (>80 mg/ dL) and Lp(a) (>100 nmol/L in GeneSTAR and >100 mg/dL in CCHS). Characteristics of the populations are shown in Table 1 .
In GeneSTAR, all 8 subjects with the phenotype were female, with 4 whites and 4 blacks ( Table 2 ). All subjects had relatively high total cholesterol, but mostly normal triglyceride levels. Only 1 subject had a significantly elevated LDLC. Apo(a) isoforms ranged in size from 500 to 750 kDa ( Table 2) , and none had small apo(a) isoforms typically associated with high Lp(a). 16, 17 Only 2 subjects had a body mass index >30, and none had diabetes mellitus. In CCHS, 8 of the 9 subjects with the phenotype were female, and all were white ( Table 3 ). The lipid values were similar to those of GeneSTAR subjects, except that the HDLC values were somewhat higher and the triglyceride values lower, in keeping with the overall CCHS population. One subject had a significantly elevated LDLC, one had a body mass index >30 kg/m 2 , and none had diabetes mellitus.
In GeneSTAR, the HDLC level of 80 mg/dL corresponded to the 95th percentile of values for the population, whereas the Lp(a) level of 100 nmol/L represented the 71st percentile, taking into account sex and race. Only 8 subjects of the 543 had combined elevations of high HDLC/Lp(a) (1.5%; Tables 1 and 2); none of whom were related. In CCHS, the HDLC level of 80 mg/dL represented the 88th percentile for the population, whereas the Lp(a) level of 100 mg/dL represented the 94th percentile. Of the 5835 subjects, only 9 (0.15%) had combined elevations of HDLC/Lp(a) of this magnitude (Tables 1 and 3 ). To further examine the striking female predominance for the high HDLC/high Lp(a) phenotype, we applied sex-and racespecific 90th and 95th percentile thresholds for both HDLC and Lp(a) to identify subjects. [30] [31] [32] In GeneSTAR, 10/13 subjects exceeding the 90th percentile for both HDLC and Lp(a) were female, whereas in CCHS, 3/4 subjects exceeding the 95th percentile were female, strongly supporting the female predominance for this phenotype.
Sequencing of SCARB1 in Subjects With the High HDLC/High Lp(a) Phenotype
In the NIH patient and the GeneSTAR cohort (Table 2) , 5 rare (expected frequency <1%) or uncommon (expected frequency 1%-10%) SCARB1 variants were found in 7 subjects, resulting in functional coding changes: a c.389C>T base change in exon 3 (subject 1, resulting in a missense serine to leucine substitution at amino acid 129), a c.4G>A base change in exon 1 (subjects 2 and 3, resulting in a missense glycine to serine substitution at amino acid 2), a c.631-14T>G base change in intron 4 near the exon 5 acceptor splice site (subject 4, resulting in deletion of exon 5), a compound mutation at c.631-53 m C>T and c.726 +54,55 m CG>CA (subject 5, intron 4 and intron 5 variants, resulting in a deletion of exon 5), and a relatively uncommon c.1495G>A polymorphism of SCARB1_v2, an alternatively spliced form of the SCARB1 gene, 33 resulting in a G499R substitution in the carboxy-terminal tail (subjects 8 and 9). All of these missense/deletion variants were heterozygous. The c.631-14T>G base change in subject 4 is located within a polypyrimidine sequence, which may affect mRNA splicing. 34 The base change in subjects 2 and 3 is located just after the ATG initiation codon and was previously found to be important for efficient protein translation. 35 The base change in subjects 8 and 9 is predicted to impair function of the translated protein.
Two additional subjects (6 and 7) were homozygous for a common c.1050C>T polymorphism (rs5888, a variant in exon 8, resulting in a synonymous arginine change at position 350). Subject 3 was heterozygous for this same variant. Although it is a synonymous polymorphism, it has been found to change RNA secondary structure and decrease protein expression. 36 In CCHS, variants were found in 6 of the 9 subjects (Table 3 ). Subjects 11 and 12 were heterozygous for a novel mutation, c.389A>G (exon 3 variant, resulting in a missense substitution of glutamic acid to glycine at position 130) in the extracellular loop of SR-B1, predicted Table 3 Subject ID  10  11  12  13  14  15  16  17  18   Age, y  60  49  53  55  44  83  63  69  80   Sex  F  F  F  M  F  F  F  F  F   Race  White  White  White  White  White  White  White  White  White   BMI  23  23  20  35  22  23  21  28 24 to impair SR-B1 function ( Table 4 ). Four additional subjects (13, 14, 15, and 16) were found to be homozygous for the common c.1050C>T polymorphism (Tables 3 and  4 ). The variabilities in Lp(a) and HDL levels in subjects with this polymorphism (Tables 2 and 3) suggest that other unidentified factors contribute to the high Lp(a)/high HDL phenotype.
. Clinical Data and SCARB1 Variants in CCHS Cohort With High HDLC/High Lp(a) Phenotype
Smoking − − − + − + − − − Diabetes mellitus − − − − − − − − − TC,
Relation Between SCARB1 Variants and Lp(a) and HDLC Levels in GeneSTAR Families
The GeneSTAR subjects in Table 2 , all of whom had variants in the SCARB1 gene, had 12 related siblings. Five of them shared one of the SCARB1 variants and were, therefore, carriers without the full high HDLC/Lp(a) phenotype. Comparing the 5 sibling carriers of SCARB1 variants (all heterozygous) with the 7 noncarriers, carriers had significantly higher levels of Lp(a) (160±47 versus 76±63 nmol/L; P=0.0097) and large HDL particles (HDL5+4, 17±5 vs 10±6 mg/dL; P<0.0001). Total HDLC level was not significantly different in carriers (52±8 versus 45±13 mg/dL; P=0.59).
There were no significant differences in other lipids or apo(a) isoforms between the groups. Results from the 5 siblings of GeneSTAR subject 4, who had a SCARB1 splice site mutation (c.631-14T>G), are shown in more detail in Figure 1 . By PCR-restriction enzyme analysis, 2 of the siblings were found to be heterozygous for the mutation, evident by the presence of 2 bands (lanes 3 and 4), and 3 were found to be homozygous for the wild-type sequence. Subjects with the mutation (lanes 3, 4, and 5) had higher Lp(a) levels and tended to have higher HDLC levels than subjects without the mutation. Two different apo(a) size isoforms of 580 and 620 kDa were found in the family, but the isoform size did not seem to correlate with Lp(a) levels.
Functional Assessment of SCARB1 Variants
We tested the effect of 4 of the identified SCARB1 variants on the uptake of cholesteryl ester from HDL and Lp(a) following expression in 293 cells. The c.386C>T (S129L) mutation (subject 1) showed a similar level of mRNA and ExAC indicates Exome Aggregation Consortium; GO-ESP, NHLBI Grand Opportunity Exome Sequencing Project; PSIC, position-specific independent count; and SR-B1, scavenger receptor class B type 1.
‡Accounts for the frequency of homozygotes. The predicted effect of genetic variants on SR-B1 function is calculated by the position-specific independent count (PSIC).
*Variant effect=actual in vitro test result. The function of the following variants were not tested: E130G (immediately adjacent to S129L), G499R (located in splice variant 2, role uncertain), and A350A (previously studied). 36 †In dbSNP.
protein expression compared with the wild-type sequence (Figure 2A ), but the mutation resulted in an ≈60% reduction in cholesteryl ester uptake from HDL 3 ( Figure 2B ) and Lp(a) ( Figure 2C ). The mutations in subjects 4 and 5, potentially affecting intron splicing 34 and altering DNA methylation pattern, 37 were tested by making wild-type and mutant types of minigenes containing exons 4 through 6 of SCARB1. Splicing of the SCARB1 minigenes was examined by reverse transcriptase PCR after transfection of 293 cells. The wild-type sequence produced a single band of 400 bp, the predicted size of a fragment containing exons 4 through 6 ( Figure 3A) . In contrast, the predominant band for the -14G or c.631-53T and c.726+54, 55 CA variants was a shorter 305-bp band. Sequencing of reverse transcriptase PCR products confirmed the absence of exon 5 in the 305 bp fragment ( Figure 3B) . A construct lacking exon 5 was transfected into the cells and was found to produce a shorter-sized protein ( Figure 3C, upper panel) , which was completely defective for cholesteryl ester uptake from both HDL and Lp(a) ( Figure 3C, lower panel) . The methylation pattern of the mutant sequence was altered compared with the wild-type sequence ( Figure I in the Data Supplement). Interestingly, wild-type SR-B1 demonstrated greater uptake of cholesteryl ester from Lp(a) than from HDL 3 , suggesting that SR-B1 may be a more important clearance pathway for Lp(a) than HDL.
The c.4G>A polymorphism found in subjects 2 and 3 was also expressed in 293 cells and, as recently described, 33 demonstrated reduced translation efficiency and decreased receptor function (Figure 4) . The common c.1050C>T polymorphism, which was found to be homozygous in 6 subjects and heterozygous in 1 (Tables 2 and 3) , has been previously associated with increased HDLC, 10,12 but a possible relationship with Lp(a) has not been reported.
Discussion
Our major finding was the association of variants in the SCARB1 gene with a previously unrecognized dyslipidemic phenotype of combined increases in HDLC and Lp(a) levels. Co-occurrence of elevated HDLC and Lp(a) levels was uncommon, found in only 1.5% of apparently healthy family subjects in GeneSTAR and 0.15% of the Copenhagen City Heart Study population. There was a striking preponderance of women with this phenotype, which persisted when sex-specific 90th and 95th percentiles for HDL and Lp(a) were used. Women have higher HDL and Lp(a) levels and may have a higher rate of synthesis of both lipid particles, 38 allowing expression of this phenotype in the presence of a functional variant in the SCARB1 gene.
Of the 18 subjects with the high HDLC/high Lp(a) phenotype, 15 had a genetic variant in SCARB1. Rare or uncommon missense or splice variants were found in 9 subjects, a much higher frequency than reported in a population with high HDLC alone 13 or in the general population (Table 4 ). Using cellular studies, we examined the function of the transcribed protein for 4 of the missense/splice variants and found decreased function in all (Figures 2-4) . The healthy siblings of GeneSTAR subjects in Table 2 who were identified as carrying a SCARB1 mutation or polymorphism had higher Lp(a) levels and an increase in large HDL subfractions compared with their siblings without the variants. Concordance of these genetic variants with increased Lp(a) levels within families provides additional support for a role for SR-B1 in the uptake of Lp(a), as well as HDLC. 5, 39, 40 Recently, a genome-wide association study 41 found that the LPA gene locus encoding Lp(a) (chromosome 6, rs1084651) and a SCARB1 locus (chromosome 12, rs838880) are associated with increased HDLC.
Our finding of an association of SCARB1 variants with elevated HDLC is consistent with previous reports [10] [11] [12] [13] and also with findings in Scarb1 knockout mice. 37, 39 Recently, among subjects with a high HDL, an individual was reported homozygous for the P376L loss of function variant in SCARB1. 14 Lp(a) was not elevated in this person, nor in others heterozygous for the P376L variant. The explanation may involve the location of this variant in the C-terminal portion of the extracellular domain, which may be less important for Lp(a) binding than the N-terminal domain, where almost all of our variants were located. 42 Our finding that SCARB1 variants are associated with both elevated HDL and elevated Lp(a) is novel and consistent with our recent finding that SR-B1 mediates cellular uptake of Lp(a) particles in vitro and the clearance of Lp(a)cholestryl ester in vivo in mice. 5 Compared with wild-type mice, transgenic mice overexpressing human SR-BI in liver showed ≈4-fold increased plasma clearance of [ 3 H] cholesteryl ether-labeled Lp(a), whereas Sr-b1 knockout mice had ≈2.5-fold decreased plasma clearance. 5 Although SR-B1 appears to bind both HDL and Lp(a) and mediate intracellular transport of lipid, the precise mechanism of binding is unknown. The binding of Lp(a) can be competed away by excess HDL, 5 and based on the selective transport of cholesteryl ester from Lp(a), 5 the binding probably occurs through the lipid rather than the protein moiety. SR-B1 probably does not have specific domains for either Lp(a) or HDL, but the 2 may compete based on the molar concentration of each lipid moiety.
Four SCARB1 mutations (c.386C>T and c.389A>G and the 2 mutations causing exon 5 deletions) were in the extracellular loop of SR-B1, which is known to be involved in ligand binding. 42, 43 Serine 129, located in this region, is conserved in several species and, when tested by sitedirected mutagenesis, was found to decrease cholesteryl ester uptake (Figure 2 ). The truncated protein missing exon 5 did not show any residual cholesteryl ester uptake activity ( Figure 3C ).
In addition, we found 2 uncommon SCARB1 variants and 1 common polymorphism previously associated with increased HDLC. Six subjects with combined elevations of HDLC and Lp(a) were homozygous for c.1050C>T (2 in GeneSTAR and 4 in CCHS), and 1 was heterozygous for both the c.1050C>T and the c.G>A polymorphism, with no single heterozygotes identified. Homozygosity for these polymorphisms may be required to produce the high HDLC/high Lp(a) phenotype. One subject with , 55 m CG>CA mutations on SCARB1 mRNA splicing and cholesteryl ester uptake. A, The effect of the mutations on mRNA splicing was determined by gel electrophoresis of reverse transcriptase polymerase chain reaction (RT-PCR) products produced from 293 cells transfected with minigenes as shown in the diagram. B, DNA sequence of RT-PCR products from transfected cells expressing either wild-type or both mutants. C, Top, A plasmid encoding the exon 5 deletion mutant (dE5) or the wild-type (W) sequence was transfected into 293 cells and tested by immunoblot for SR-B1 (scavenger receptor class B type 1) and GAPDH protein. Bottom, 293 cells were transfected with either the CAT control plasmid (CAT), exon 5 deletion mutant (dE5), wild-type (W) SCARB1 sequence or an equimolar mixture of the wild-type sequence and the mutant sequence (W+dE5). Cells were tested for cholesteryl ester uptake from either 10 μg/mL of radiolabeled lipoprotein (a) (Lp(a)) or high-density lipoprotein (HDL). Results are expressed as the mean±1 SD from 3 independent experiments. IV4-14g indicates transfected with mutant c.631-14G; IV4-IV5 Mt, transfected with mutant c.631-T and c.726 CA; Mock, transfected with empty vector; and Wt, wild-type.
the phenotype was homozygous for the c.G>A polymorphism in Exon 1 (N-terminal intracellular domain). Two subjects were heterozygous for the uncommon c.1495G>A polymorphism, which is present only in subjects of African descent. This polymorphism encodes an alternative spliced form of SCARB1 containing a different carboxy-terminal cytoplasmic tail 44 and would be predicted to also affect SR-B1 function; however, we did not test this.
The effect of the high HDLC/high Lp(a) phenotype on human cardiovascular disease is not known. High HDLC may reduce cardiovascular risk; however, not all conditions that raise HDL are protective. Scarb1 null mice, for example, have increased atherosclerosis, 8, 9 despite increased HDLC levels. 39, 40 Zanoni et al 14 found that elevated HDL related to heterozygosity of the P376L SCARB1 variant was associated with an increased risk of CAD. Raising HDL with drugs has shown no benefit. 45 On the other hand, Lp(a) is generally viewed as proatherogenic. 16, 24, 46 A large Mendelian randomization study demonstrated that a genetically determined doubling of Lp(a) was associated with a 22% increase in risk. 47 Additional studies may determine whether variants in SCARB1 have an impact on atherosclerosis.
There remains a lack of specific Lp(a)-lowering therapies to test whether Lp(a) should be reduced in patients at risk for CAD. For example, nicotinic acid produces a 20% to 40% lowering of Lp(a), but also reduces LDLC and triglycerides and raises HDLC. 48 The mechanism seems to be a reduction in Lp(a) synthesis, without an effect on catabolism or clearance, so it is likely to be independent of SR-B1. 49 Inhibitors of PCSK9 (proprotein convertase subtilisin/kexin type 9) lower Lp(a) by 20% to 30% in addition to their primary effect on LDLC. 49 The mechanism may be related to reduced synthesis caused by a reduction in apolipoprotein B synthesis or availability, 49 but is probably independent of the SR-B1 receptor. 50 Lp(a) could be reduced by increasing function of SR-B1, although HDLC might also be reduced. Understanding whether, how, and under what circumstances to lower Lp(a) is important and will require future welldesigned clinical studies. Figure 4 . Effect of c.4G>A (G2S) mutation on SCARB1 translation. A, Plasmids containing the wild-type (G) or mutant (A) sequence of SCARB1 were transfected into 293 cells. Cell clones containing similar levels of the expression plasmid from the wild-type or mutant sequence underwent reverse transcriptase polymerase chain reaction (RT-PCR) for SCARB1 and actin mRNA levels (A) and immunoblot for SR-B1 (scavenger receptor class B type 1) and GAPDH protein (B). The ratio of SCARB1 to GAPDH was determined by densitometry and tested for statistical significance by t test.
